Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer

Christopher B Morse; Julia A Elvin; Laurie M Gay; John B Liao

doi:10.1016/j.gore.2017.06.013

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer

Gynecol Oncol Rep. 2017 Jun 27;21:78-80. doi: 10.1016/j.gore.2017.06.013. eCollection 2017 Aug.

Authors

Christopher B Morse¹, Julia A Elvin², Laurie M Gay², John B Liao¹

Affiliations

¹ Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
² Foundation Medicine, Cambridge, MA, United States.

Abstract

•We report an ovarian cancer patient with a prolonged response to immunotherapy.•Comprehensive genomic profiling may detect patients who benefit from immunotherapy.•Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Publication types

Case Reports

Grant support

T32 CA009515/CA/NCI NIH HHS/United States